Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- LPCN
- Price
- 9.45
- Stock movement up
- +0.79 (9.12%)
- Company name
- Lipocine Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 52.47M
- Ent value
- 50.50M
- Price/Sales
- 12.14
- Price/Book
- 3.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 166.95%
- 3 year return (CAGR)
- 159.62%
- 5 year return (CAGR)
- 35.88%
- 10 year return (CAGR)
- 0.41%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LPCN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 12.14 |
| Price to Book | 3.71 |
| EV to Sales | 11.68 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.55M |
| EPS (TTM) | -1.01 |
| FCF per share (TTM) | -0.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.32M |
| Gross profit (TTM) | 2.19M |
| Operating income (TTM) | -6.31M |
| Net income (TTM) | -5.48M |
| EPS (TTM) | -1.01 |
| EPS (1y forward) | -1.81 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 50.57% |
| Operating margin (TTM) | -145.98% |
| Profit margin (TTM) | -126.66% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.90M |
| Net receivables | 115.27K |
| Total current assets | 15.93M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.39M |
| Total assets | 16.07M |
| Accounts payable | 861.45K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.93M |
| Total liabilities | 1.93M |
| Shareholder's equity | 14.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.14M |
| Capital expenditures (TTM) | 10.03K |
| Free cash flow (TTM) | -5.15M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -38.72% |
| Return on Assets | -34.06% |
| Return on Invested Capital | -38.72% |
| Cash Return on Invested Capital | -36.41% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.66 |
| Daily high | 9.78 |
| Daily low | 8.66 |
| Daily Volume | 78K |
| All-time high | 20.00 |
| 1y analyst estimate | 10.88 |
| Beta | 1.01 |
| EPS (TTM) | -1.01 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LPCN | S&P500 | |
| Current price drop from All-time high | -52.75% | -1.82% |
| Highest price drop | -98.78% | -56.47% |
| Date of highest drop | 5 May 2023 | 9 Mar 2009 |
| Avg drop from high | -80.69% | -10.84% |
| Avg time to new high | 1540 days | 12 days |
| Max time to new high | 3080 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
52.47M
Marketcap category
Small-cap
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Employees
16
Website
Investor relations
-
SEC filings
CEO
Mahesh V. Patel
Country
USA
City
Salt Lake City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page